Trevi Therapeutics, Inc.
$15.4
▲
3.11%
2026-04-21 09:55:00
www.trevitherapeutics.com
NGM: TRVI
Explore Trevi Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.96 B
Current Price
$15.4
52W High / Low
$15.76 / $5.38
Stock P/E
—
Book Value
$1.43
Dividend Yield
—
ROCE
-26.85%
ROE
-30.23%
Face Value
—
EPS
$-0.32
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
34
Beta
1
Debt / Equity
0.41
Current Ratio
19.66
Quick Ratio
19.66
Forward P/E
-23.35
Price / Sales
—
Enterprise Value
$1.51 B
EV / EBITDA
-30.62
EV / Revenue
—
Rating
None
Target Price
$21.55
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Spero Therapeutics, Inc. | $2.84 | 19.18 | $164.41 M | — | 11.92% | 16.3% | $3.22 / $0.57 | $1.05 |
| 2. | Cogent Biosciences, Inc. | $37 | — | $6.05 B | — | -38.16% | -73.7% | $43.73 / $4.12 | $3.4 |
| 3. | Absci Corporation | $3.95 | — | $547.82 M | — | -64.8% | -62.5% | $5.23 / $2.24 | $1.25 |
| 4. | Lyell Immunopharma, Inc. | $24.89 | — | $559.6 M | — | -69.37% | -86.98% | $45 / $7.65 | $11.68 |
| 5. | Palisade Bio, Inc. | $2.5 | — | $414.71 M | — | -13.92% | -24.52% | $2.64 / $0.53 | $0.81 |
| 6. | EyePoint, Inc. | $15.07 | — | $1.26 B | — | -74.45% | -72.19% | $19.11 / $5.3 | $3.7 |
| 7. | Celularity Inc. | $1.24 | — | $35.47 M | — | -48.8% | -232.51% | $4.35 / $1.01 | $-0.71 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -10.22 M | -13.92 M | -13.72 M | -11.47 M | -12.24 M |
| Net Profit | -8.32 M | -11.8 M | -12.3 M | -10.34 M | -11.41 M |
| EPS in Rs | -0.06 | -0.09 | -0.1 | -0.08 | -0.09 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -49.33 M | -51.52 M | -33.92 M | -29.91 M |
| Net Profit | -42.76 M | -47.91 M | -29.07 M | -29.15 M |
| EPS in Rs | -0.33 | -0.37 | -0.23 | -0.23 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 193.44 M | 110.9 M | 89.4 M | 123.02 M |
| Total Liabilities | 10.2 M | 11.26 M | 6.86 M | 15.56 M |
| Equity | 183.24 M | 99.64 M | 82.55 M | 107.46 M |
| Current Assets | 191.66 M | 109.43 M | 87.55 M | 122.62 M |
| Current Liabilities | 9.75 M | 10.51 M | 5.82 M | 13.4 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -42.09 M | -38.26 M | -31.71 M | -28.18 M |
| Investing CF | -94.11 M | -21.53 M | 59.43 M | -107.37 M |
| Financing CF | 121.01 M | 61.48 M | -7.91 M | 111.31 M |
| Free CF | -42.1 M | -38.29 M | -31.85 M | -28.33 M |
| Capex | -0.01 M | -0.04 M | -0.14 M | -0.16 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -64.84% | 0.3% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.